Abstract: Embodiments of the invention relate to fortified food and dietary supplement products which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with plant products and iridoids. A study was performed to evaluate the iridoid content, as well as the in vitro and in vivo bioactivities, of a beverage containing noni fruit, Cornelian cherries, and olive leaf extract. The major iridoids present were identified as asperulosidic acid, deacetylasperulosidic acid, oleuropein, morroniside, loganic acid, and loganin In the 2,2-Diphenylpicrylhydrazyl (DPPH) radical scavenging assay, remarkably high in vitro antioxidant activity was observed, with an IC50 of 3.8 ?L/mL. In vivo bioactivities were evaluated in type 2 diabetic Sprague Dawley rats.

Abstract: Embodiments of the invention relate to fortified food and dietary supplement products which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with Morinda citrifolia and iridoids.

Abstract: Fortified food and dietary supplement products may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with plant products and iridoids. A study was performed to evaluate the iridoid content, as well as the in vitro and in vivo bioactivities, of a beverage containing noni fruit, Cornelian cherries, and olive leaf extract. The major iridoids present were identified as asperulosidic acid, deacetylasperulosidic acid, oleuropein, morroniside, loganic acid, and loganin In the 2,2-Diphenylpicrylhydrazyl (DPPH) radical scavenging assay, remarkably high in vitro antioxidant activity was observed, with an IC50 of 3.8 ?L/mL. In vivo bioactivities were evaluated in type 2 diabetic Sprague Dawley rats.

Abstract: Implementation is directed to selectively inhibiting estrogen production and providing estrogenic effects in a human body. A dietary supplement includes a processed Morinda citrifolia product that is used to inhibit aromatase or aromatase enzymes that function to convert androgens to estrogens, inhibit receptors from binding with estrogen, and reduce and/or regulate estrogen production, as well as reduce the amount of estrogen produced within the body and regulating such production. The dietary supplement further provides estrogenic effects. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: Fortified food and dietary supplement products may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with plant products and iridoids. A study was performed to evaluate the iridoid content, as well as the in vitro and in vivo bioactivities, of a beverage containing noni fruit, Cornelian cherries, and olive leaf extract. The major iridoids present were identified as asperulosidic acid, deacetylasperulosidic acid, oleuropein, morroniside, loganic acid, and loganin In the 2,2-Diphenylpicrylhydrazyl (DPPH) radical scavenging assay, remarkably high in vitro antioxidant activity was observed, with an IC50 of 3.8 ?L/mL. In vivo bioactivities were evaluated in type 2 diabetic Sprague Dawley rats.

Abstract: Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Abstract: Embodiments of the invention relate to fortified food and dietary supplement products which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with plant products and iridoids.

Abstract: Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Acai and iridoids.

Abstract: Embodiments of the invention relate to fortified food and dietary supplement products which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relates to the administration of products enhanced with Morinda citrifolia and iridoids.

Abstract: The invention relates to the administration of products enhanced with Morinda citrifolia L. in order to inhibit anaerobes, gram negative bacteria, protozoa and other microbial growth related to various maladies and illnesses which result in detrimental physiological effects.

Abstract: The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.

Abstract: Implementation is directed to selectively inhibiting estrogen production and providing estrogenic effects in a human body. A dietary supplement includes a processed Morinda citrifolia product that is used to inhibit aromatase or aromatase enzymes that function to convert androgens to estrogens, inhibit receptors from binding with estrogen, and reduce and/or regulate estrogen production, as well as reduce the amount of estrogen produced within the body and regulating such production. The dietary supplement further provides estrogenic effects. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.